Clostridium butyricum MIYAIRI 588 strain has been used as a probiotic for both non-antimicrobial induced diarrhea and antimicrobial associated diarrhea in humans.
Clostridium butyricum MIYAIRI (CBM) was discovered from feces by Dr. Miyairi in 1933.CBM inhibit to putrefying bacteria and increase to beneficial bacteria (especially bifidobacteria and lactobacilli). Since their first commercial production in 1940, probiotics based on CBM have been widely used as ethical and OTC drugs, veterinary drugs, feed and food supplements.
Origin or History of Development
Clostridium butyricum MIYAIRI (known as CBM) is a number of C.butyricum, a butyric acid producing spore forming obligate anaerobe, which found in soil and the intestine in humans and animals. It was discovered by Dr. Miyairi in 1933 at the department of Hygiene at Chiba Medical College (now located at the Chiba University School of Medicine).
The mechanism by which CBM controls diarrhea is based on several properties of CBM. For example,CBM has been shown to have antagonistic interaction against Candida albicans, Clostridium difficile , enterotoxigenic Escherichia coli, Klebsiella spp., Salmonella spp. and Vibrio spp.
In addition, butyric acid has a proliferative effect on mucosal cells in the intestine, suggesting that, butyric acid has therapeutic efficiency against inflammatory bowel disease.